An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)

Status:
Not yet recruiting

Trial end date:
2025-06-01

Target enrollment:

Participant gender:

To assess whether nivolumab+nab-paclitaxel combination results in patients with muscle-invasive bladder cancer

Phase 2

IRCCS San Raffaele

Bristol-Myers Squibb

Nivolumab
Paclitaxel